Brenner Bluma, Routy Jean-Pierre, Quan Yudong, Moisi Daniela, Oliveira Maureen, Turner Dan, Wainberg Mark A
McGill University AIDS Centre, Jewish General Hospital and McGill University Health Centre, Montreal, Quebec, Canada.
AIDS. 2004 Aug 20;18(12):1653-60. doi: 10.1097/01.aids.0000131377.28694.04.
The authors previous studies documented persistence of multidrug resistance (MDR) acquired in five primary HIV-1 infection (PHI) cases for 1-2 years in the absence of antiretroviral treatment. This study characterizes the evolution of transmitted wild-type (WT) (n = 15), resistant (n = 10), and MDR (n = 6) infections. Long-term persistence of MDR infections (2-7 years), leading to one observed MDR superinfection is documented.
Genotypic changes in circulating viral quasi-species were evaluated over 1.5-7 years in patients (n = 31) enrolled in the PHI study. Sequencing of reverse transcriptase and protease regions identified nucleotide substitutions in the viral quasi-species and mutations at sites implicated in resistance to antiretroviral drugs. Phylogenetic and clonal analysis were performed to confirm one observed superinfection.
Patients acquiring WT, drug-resistant and MDR infections showed little quasi-species evolution (> 99.6% homology) for more than 1.5 years, regardless of route of transmission. Transmitted resistance mutations (other than 184V) persisted for 2-7 years. MDR persistence in two PHI cases contrasted with the corresponding rapid reversion of MDR infections to WT in their partners following treatment interruption. One MDR transmission eliciting low-level viremia resulted in clearance of the original MDR infection followed by re-infection with a second heterologous MDR strain from a different partner. Phylogenetic and clonal analysis of source and index partner confirmed the superinfection. Both MDR species showed approximately 13-fold reductions in replication capacity relative to the homologous WT strain isolated from the source partner.
Genotypic analysis in PHI may identify superinfection and MDR infections that represent important determinants of virological and treatment outcome.
作者之前的研究记录了5例原发性HIV-1感染(PHI)病例在未接受抗逆转录病毒治疗的情况下获得的多药耐药性(MDR)持续存在1至2年。本研究描述了传播的野生型(WT)(n = 15)、耐药(n = 10)和MDR(n = 6)感染的演变情况。记录了MDR感染的长期持续存在(2至7年),导致1例观察到的MDR重叠感染。
在参与PHI研究的患者(n = 31)中,评估了1.5至7年期间循环病毒准种的基因变化。逆转录酶和蛋白酶区域的测序确定了病毒准种中的核苷酸取代以及与抗逆转录病毒药物耐药性相关位点的突变。进行了系统发育和克隆分析以确认1例观察到的重叠感染。
获得WT、耐药和MDR感染的患者,无论传播途径如何,在超过1.5年的时间里病毒准种进化很少(同源性> 99.6%)。传播的耐药突变(除184V外)持续存在2至7年。2例PHI病例中的MDR持续存在,与治疗中断后其伴侣中MDR感染迅速恢复为WT形成对比。1次引发低水平病毒血症的MDR传播导致原始MDR感染清除,随后被来自不同伴侣的第二种异源MDR菌株重新感染。对来源和索引伴侣进行系统发育和克隆分析证实了重叠感染。相对于从来源伴侣分离的同源WT菌株,两种MDR毒株的复制能力均降低了约13倍。
PHI中的基因分析可能识别出重叠感染和MDR感染,它们是病毒学和治疗结果的重要决定因素。